Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from ...

Biogen will receive rights to commercialize zorevunersen outside the US, Canada, and Mexico, paying $165 million upfront and other milestone payments.

Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet ...

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million ...

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...

Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...

Under the terms of the deal, Bedford, Mass.-based Stoke (STOK) will retain exclusive rights for the treatment called zorevunersen in the U.S., Canada and Mexico, while Cambridge, Mass.-based Biogen ...

UNHCR, the UN Refugee Agency works to ensure that everybody has the right to seek asylum and find safe refuge, having fled violence, persecution or war at home. Since 1950, we have faced multiple ...

The company has a current ratio of 1.26, a quick ratio of 0.80 and a debt-to-equity ratio of 0.28. Biogen has a twelve month low of $139.71 and a twelve month high of $251.99. The firm has a ...

Below is an image shared on the Nike SNKRS app yesterday that broke down the NBHD doors stocking the limited “Bred” Air Jordan 1 High ’85 next month. A majority of the shops are located in ...